Multivalent vaccine composition

Details for Australian Patent Application No. 2001281895 (hide)

International Classifications

Event Publications

28 April 2005 Application Accepted

Published as AU-B-2001281895

9 June 2005 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 20 May 2005. Address for service in Australia - Phillips Ormonde & Fitzpatrick Level 21 367 Collins Street Melbourne VIC 3000 2003

15 September 2005 Standard Patent Sealed

27 October 2005 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 20 May 2005

17 February 2011 Extension of Term of Standard Patents

GlaxoSmithKline Biologicals s.a. The earliest first regulatory approval date provided by the patentee 05 Aug 2010 For the goods MENITORIX Combined Hib-MenC conjugate vaccine Powder for injection vial plus diluent syringe Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

17 March 2011 Extension of Term of Standard Patents

GlaxoSmithKline Biologicals s.a. The earliest first regulatory approval date provided by the patentee 05 Aug 2010 For the goods MENITORIX Combined Hib-MenC conjugate vaccine Powder for injection vial plus diluent syringe Address for service in Australia: Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000

11 August 2011 Extension granted

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.